AVM Awarded SBIR Grant From National Cancer Institute

Seattle, June 11, 2020 – AVM Biotechnology has been awarded a National Cancer Institute Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH) to study the use of their lead molecule AVM0703 as a preconditioning agent to allow safe and efficient delivery of therapeutic immune cells for cancer treatment.